Verition Fund Management
HBIO icon

Verition Fund Management’s Harvard Bioscience HBIO Stock Holding History

Verition Fund Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,237
Closed -$7K – 3723
2025
Q1 		$7K Sell
1,237
-1,979
-62% -$25.3K ﹤0.01% 3264
2024
Q4 		$67.9K Sell
3,216
-186
-5% -$4.27K ﹤0.01% 3111
2024
Q3 		$91.5K Sell
3,402
-429
-11% -$12.6K ﹤0.01% 3007
2024
Q2 		$109K Buy
+3,831
New +$134K ﹤0.01% 2721
2023
Q3 		– Sell
-2,541
Closed -$139K – 2477
2023
Q2 		$139K Buy
+2,541
New +$139K ﹤0.01% 1930

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verition Fund Management's HBIO Position: Q2 2025 in Review

Verition Fund Management sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 1,237 shares — an estimated $7K sold.

Verition Fund Management first reported a position in HBIO in Q2 2023 and held it in 5 quarters. The position peaked at $139K in Q2 2023. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

  • Verition Fund Management reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 1,237 Harvard Bioscience shares in Q2 2025, an estimated $7K.
  • Verition Fund Management first reported a position in Harvard Bioscience in Q2 2023 and held it in 5 quarters.
  • Verition Fund Management's Harvard Bioscience position peaked at $139K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.